New data by academic researchers highlights biological activity of simufilam on filamin a

Austin, texas, may 08, 2023 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a clinical-stage biotechnology company, today announced new data from european researchers that highlight the bioactivity of simufilam on the filamin a (flna) protein. prior research has shown that flna is altered in pituitary tumor cells, leading to impaired cell signaling. new in vitro data now show that simufilam can reverse this flna alteration in pituitary tumor cells, leading to improved cell signaling. the data also suggest that improved cell signaling may enhance the clinical efficacy of an fda-approved drug used to manage a type of pituitary tumor.
SAVA Ratings Summary
SAVA Quant Ranking